Robert Wessman, the Icelandic entrepreneur who built Actavis into a generics powerhouse and then sold out, has decided get into the biosimilars business. He has talked his home country into helping finance his plans.
Johnson & Johnson's executives preparing for upcoming trials alleging the company's Ethicon division sold faulty vaginal mesh that harmed legions of women are already facing a bombshell accusation: patients' attorneys accuse employees of destroying or losing hundreds of thousands of vital product documents.
Insurers also stand to gain plenty from Johnson & Johnson's $2.5 billion-plus offer to settle 8,000 lawsuits involving faulty metal hip implants. Bloomberg reported that the conglomerate will fork over as much as $1 billion to insurers who covered patients' cost of removing the now-recalled ASR implants.
GlaxoSmithKline is broadening its reach in the big U.S. R&D field in coming months, ramping up satellite innovation centers in Cambridge, MA, and San Diego where its teams can shepherd a growing flock of research partnerships while hunting down new technologies and spawning biotech startups.
Johnson & Johnson's $2.5 billion-plus agreement to settle as many as 8,000 lawsuits over faulty metal hip implants made by its subsidiary, DePuy, is already getting pushback. Patients complain their attorneys and the company itself gain more than they do from the deal, and if discontent rises, it could place the overall agreement at risk.
No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important....
Johnson & Johnson and its partner Medivir won a green light from the FDA late on Friday to begin marketing their hepatitis C drug simeprevir, which will now be sold as Olysio.
Johnson & Johnson won FDA approval for Olysio (simeprevir), its drug to treat hepatitis C, in combination with standard treatments interferon and ribavirin.
Pharmacyclics and Johnson & Johnson are riding high on an accelerated approval for the blockbuster hopeful Imbruvica, and now they've tapped Catalent to aid in commercial manufacturing and ongoing clinical trials for the cancer drug.
The whole pay-to-delay issue has gotten a lot of attention in the U.S., particularly with the U.S. Supreme Court this year making it easier for regulators and payers to attack those deals. But Europe also thinks the deals tend to stink for patients and government payers, and it has begun issuing fines to alleged violators. Next up looks to be Novartis and Johnson & Johnson.